Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells

Blood

Volumn 122, Issue 7, 2013, Pages 1182-1191

  Hahn, Susanne A ^a   Stahl, Heiko F ^b   Becker, Christian ^a   Correll, Anita ^a   Schneider, Franz Joseph ^b   Tuettenberg, Andrea ^a   Jonuleit, Helmut ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN A REPETITIONS PREDOMINANT; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DNA BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; LRRC32 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; RAG2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NEWBORN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT; ANIMAL; APOPTOSIS; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKINS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

EID: 84887210986     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-474478     Document Type: Article

References (43)

1. Cerwenka A, Swain SL. TGF-beta1: immunosuppressant and viability factor for T lymphocytes. Microbes Infect. 1999;1(15): 1291-1296.
2. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12(2):171-181.
3. Gorelik L, Flavell RA. Transforming growth factorbeta in T-cell biology. Nat Rev Immunol. 2002; 2(1):46-53.
4. Stockis J, Colau D, Coulie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol. 2009;39(12):3315-3322.
5. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003; 116(Pt 2):217-224.
6. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11): 857-869.
7. Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGFbeta requires the latent TGF-beta binding protein-1. J Cell Biol. 2004;165(5):723-734.
8. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93(7):1159-1170.
9. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999; 96(3):319-328.
10. Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol. 1995;155(3): 1450-1459.
11. Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem. 2005;280(9): 7409-7412.
12. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007;109(8):3260-3269.
13. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D. Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS ONE. 2008;3(7):e2705.
14. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP31 regulatory T cells. Proc Natl Acad Sci USA. 2009; 106(32):13445-13450.
15. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D. Expression of GARP selectively identifies activated human FOXP31 regulatory T cells. Proc Natl Acad Sci USA. 2009;106(32): 13439-13444.
16. Wang R, Zhu J, Dong X, Shi M, Lu C, Springer TA. GARP regulates the bioavailability and activation of TGFb. Mol Biol Cell. 2012;23(6): 1129-1139.
17. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(1) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000; 192(9):1213-1222.
18. Jonuleit H, Schmitt E. Regulatory T-cells in antitumor therapy: isolation and functional testing of CD41CD251 regulatory T-cells. Methods Mol Med. 2005;109:285-296.
19. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(1)CD25(1) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193(11): 1285-1294.
20. Tuettenberg A, Huter E, Hubo M, et al. The role of ICOS in directing T cell responses: ICOSdependent induction of T cell anergy by tolerogenic dendritic cells. J Immunol. 2009; 182(6):3349-3356.
21. Kirberg J, Berns A, von Boehmer H. Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules. J Exp Med. 1997; 186(8):1269-1275.
22. Becker C, Taube C, Bopp T, et al. Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD41CD251 regulatory T cells. Blood. 2009; 114(6):1263-1269.
23. Andersson J, Tran DQ, Pesu M, et al. CD41 FoxP31 regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med. 2008;205(9):1975-1981.
24. D'Alise AM, Ergun A, Hill JA, Mathis D, Benoist C. A cluster of coregulated genes determines TGFbeta-induced regulatory T-cell (Treg) dysfunction in NOD mice. Proc Natl Acad Sci USA. 2011; 108(21):8737-8742.
25. Paiva RS, Lino AC, Bergman ML, et al. Recent thymic emigrants are the preferential precursors of regulatory T cells differentiated in the periphery. Proc Natl Acad Sci USA. 2013;110(16): 6494-6499.
26. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14(4): 307-308.
27. Probst-Kepper M, Geffers R, Kröger A, et al. GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med. 2009; 13(9B):3343-3357.
28. Edwards JP, Fujii H, Zhou AX, Creemers J, Unutmaz D, Shevach EM. Regulation of the Expression of GARP/Latent TGF-b1 Complexes on Mouse T Cells and Their Role in Regulatory T Cell and Th17 Differentiation. J Immunol. 2013; 190(11):5506-5515.
29. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C. In vitro generation of CD41 CD251 regulatory cells from murine naive T cells. Nat Protoc. 2007;2(7):1789-1794.
30. Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O'Shea JJ. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 2010;21(6):425-434.
31. Hwang ES. Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med J. 2010;51(4): 484-491.
32. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24: 99-146.
33. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-3384.
34. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(1) regulatory T cells convey suppressor activity to conventional CD4(1) T helper cells. J Exp Med. 2002;196(2):255-260.
35. Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble and membrane-bound TGF-b-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS ONE. 2013; 8(3):e59456.
36. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000; 95(9):2754-2759.
37. Banovic T, MacDonald KP, Morris ES, et al. TGFbeta in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106(6):2206-2214.
38. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol. 2003;31(11): 1044-1050.
39. Weigmann B, Schughart N, Wiebe C, et al. Allergen-induced IgE-dependent gut inflammation in a human PBMC-engrafted murine model of allergy. J Allergy Clin Immunol. 2012;129(4): 1126-1135.
40. Martin H, Reuter S, Dehzad N et al. CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J Allergy Clin Immunol. 2012;129(2):521-528.
41. Mavin E, Ahmed SS, O'Boyle G, et al. Regulatory T cells inhibit CD8(1) T-cell tissue invasion in human skin graft-versus-host reactions. Transplantation. 2012;94(5):456-464.
42. Sun K, Hsiao HH, Li M, et al. IFN-g receptordeficient donor T cells mediate protection from graft-versus-host disease and preserve graftversus-tumor responses after allogeneic bone marrow transplantation. J Immunol. 2012;189(4): 2033-2042.
43. Koenecke C, Czeloth N, Bubke A, et al. Alloantigenspecific de novo-induced Foxp31Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol. 2009;39(11):3091-3096.